

Mylab steps into vaccine and therapeutics segment

11 February 2022 | News

Partners with Shilpa Biologicals



Pune-based startup Mylab Discovery Solutions has announced its foray into the vaccine and therapeutics segment with its strategic tie-up with Shilpa Biologicals, a 100 per cent subsidiary of Shilpa Medicare, a specialist manufacturer of vaccine and wide variety of biologicals.

Starting with COVID-19 vaccine manufacturing opportunity, the parties plan to strengthen the relationship by expanding the product portfolio in various other areas including various biosimilars, other vaccines & diagnostics.

Mylab plans to develop world-class diagnostics, vaccines and therapeutics to augment its presence in the healthcare market. The company will leverage the technical expertise of Shilpa Biologicals in development and manufacture of biopharmaceuticals through its world class facility at Dharwad.

Shilpa Biologicals will utilise its integrated R&D cum manufacturing facility in Dharwad, spanning over 11 acres, to cater to these requirements. This collaboration will also be developing novel technologies that can enable production of safe, efficacious and costeffective vaccines and therapeutics. The first vaccine project under this long-term partnership is currently under final evaluation phase and the manufacturing is expected to start by March 2022.

Hasmukh Rawal, Managing Director of Mylab Discovery Solutions, said "Our vision is to develop a complete ecosystem around health of a patient. We want to ensure that from a provider to a patient - all should get a fair value in the system. For this to happen, the current models of care have to change and it is only possible to do with an integrated approach — from testing to treatment."